Pfizer Reports Phase II Data for Atirmociclib in Breast Cancer After Prior CDK4/6 Inhibitor Therapy
Pfizer announced topline results from the randomized Phase II FOURLIGHT-1 trial evaluating atirmociclib in breast cancer patients whose disease had progressed on prior CDK4/6 inhibitor therapy. The study, which enrolled 264 adults with HR-positive, HER2-negative advanced or metastatic breast cancer across 14 countries, met its primary endpoint of investigator-assessed progression-free survival, with atirmociclib plus fulvestrant demonstrating a 40% reduction in the risk of disease progression or death compared with fulvestrant alone or everolimus plus exemestane [HR: 0.60 (95% CI: 0.440–0.825); p=0.0007]. These are the first randomized Phase II data for atirmociclib, which Pfizer describes as a CDK4 inhibitor of the next generation, selectively targeting CDK4 rather than both CDK4 and CDK6.
The FOURLIGHT-1 trial was an open-label, three-arm study comparing atirmociclib plus fulvestrant against two established regimens used in the second-line metastatic setting: fulvestrant monotherapy and everolimus combined with exemestane. Patients were required to have progressed after CDK4/6 inhibitor-based treatment, and notably, more than 90% initiated atirmociclib within three months of their last CDK4/6 inhibitor regimen. The company said PFS benefit was consistent across all prespecified subgroups, including performance status, menopausal status, presence of visceral disease, duration of prior CDK4/6 inhibitor treatment (less than or greater than 12 months), and regardless of which CDK4/6 inhibitor had been received previously. Overall survival, a secondary endpoint, was not mature at the time of analysis, with approximately 20% of participants having experienced an event. Secondary endpoints also include objective response rate, duration of response, and clinical benefit response, though the company did not disclose data for these measures.
On safety, Pfizer reported that 6.4% of patients discontinued atirmociclib due to treatment-emergent adverse events. The company characterized the safety profile as manageable and consistent with prior studies, stating that no new safety signals were identified. Detailed safety and efficacy data have not yet been published; the company said results will be submitted for presentation at a future medical meeting.
Pfizer Atirmociclib and the Rationale for Selective CDK4 Inhibition
Atirmociclib is an oral, investigational inhibitor of cyclin-dependent kinase 4, a protein that plays a central role in regulating cell cycle progression. In HR-positive breast cancer, CDK4 partners with cyclin D to phosphorylate the retinoblastoma protein, releasing transcription factors that drive cells from the G1 phase into S phase and enabling proliferation. The currently approved CDK4/6 inhibitors — palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly) — inhibit both CDK4 and CDK6. Pfizer has positioned atirmociclib as a selective CDK4 inhibitor, which in theory could reduce CDK6-mediated toxicities such as neutropenia, a frequent dose-limiting side effect of the dual inhibitors. Whether this selectivity translates into a clinically distinct tolerability profile remains to be confirmed with full data disclosure.
The FOURLIGHT-1 trial results are notable in part because the patient population — those progressing soon after CDK4/6 inhibitor therapy — represents a setting with limited treatment options and no consensus standard of care. Everolimus plus exemestane, one of the comparator arms, received US FDA approval in 2012 based on the BOLERO-2 trial for HR-positive, HER2-negative advanced breast cancer after failure of a nonsteroidal aromatase inhibitor, though this regimen predates the widespread adoption of CDK4/6 inhibitors in the first-line setting. Fulvestrant monotherapy, the other comparator, is commonly used but yields modest efficacy in the post-CDK4/6 inhibitor population.
FOURLIGHT-1 Trial Results in the Post-CDK4/6 Inhibitor Landscape
The question of how to treat HR-positive, HER2-negative metastatic breast cancer after progression on a CDK4/6 inhibitor has become one of the most active areas of clinical investigation. The three approved CDK4/6 inhibitors — palbociclib, ribociclib, and abemaciclib — have become standard first-line therapy in combination with endocrine agents, meaning that virtually all patients progressing to second-line treatment have already received one of these drugs. Whether continued CDK4/6 pathway inhibition after prior exposure can yield further benefit has been debated, and several trials have explored different strategies.
Cross-trial comparisons are limited by differences in study design, duration, patient populations, and lines of prior therapy. With that caveat, the hazard ratio of 0.60 reported for atirmociclib plus fulvestrant in FOURLIGHT-1 can be placed alongside data from other second-line studies in this population. The Phase III MAINTAIN trial, which evaluated ribociclib plus fulvestrant or exemestane versus placebo plus endocrine therapy after progression on a CDK4/6 inhibitor, reported a PFS hazard ratio of 0.57 (95% CI: 0.39–0.84) favoring ribociclib. The Phase III postMONARCH trial, evaluating abemaciclib plus fulvestrant versus placebo plus fulvestrant after prior CDK4/6 inhibitor therapy, reported a PFS hazard ratio of 0.73 (95% CI: 0.57–0.95). These comparisons are indirect and should be interpreted with caution given differences in trial populations, comparator arms, and study design.